These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9055839)

  • 1. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone.
    McGee MD
    J Clin Psychiatry; 1997 Jan; 58(1):32-3. PubMed ID: 9055839
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission of self-mutilation in a patient with borderline personality during risperidone therapy.
    Khouzam HR; Donnelly NJ
    J Nerv Ment Dis; 1997 May; 185(5):348-9. PubMed ID: 9171814
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder.
    Hough DW
    J Clin Psychiatry; 2001 Apr; 62(4):296-7. PubMed ID: 11379847
    [No Abstract]   [Full Text] [Related]  

  • 4. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder.
    Chengappa KN; Ebeling T; Kang JS; Levine J; Parepally H
    J Clin Psychiatry; 1999 Jul; 60(7):477-84. PubMed ID: 10453803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-mutilation and suicide attempts: relationships to bipolar disorder, borderline personality disorder, temperament and character.
    Joyce PR; Light KJ; Rowe SL; Cloninger CR; Kennedy MA
    Aust N Z J Psychiatry; 2010 Mar; 44(3):250-7. PubMed ID: 20180727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of borderline personality disorder with opioid antagonists: buprenorphine, nalmefene, naloxone and naltrexone in the treatment of dissociative symptoms, self-mutilation and suicidal behavior].
    García MC
    Vertex; 2020 Apr; XXX(148):1-10. PubMed ID: 33890928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of dissociative symptoms in borderline personality disorder with naltrexone: supplementary comments].
    Schmahl C; Bohus M
    Nervenarzt; 2000 May; 71(5):427. PubMed ID: 10846724
    [No Abstract]   [Full Text] [Related]  

  • 8. Female genital self-mutilation: case reports and literature review.
    Wise TN; Dietrich AM; Segall E
    J Sex Marital Ther; 1989; 15(4):269-74. PubMed ID: 2693747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent suicide attempts, self-mutilation, and binge/purge behavior: a case report.
    Schinagle M
    Harv Rev Psychiatry; 2002; 10(6):353-63. PubMed ID: 12485981
    [No Abstract]   [Full Text] [Related]  

  • 10. Naltrexone treatment of self-injurious thoughts and behaviors.
    Sonne S; Rubey R; Brady K; Malcolm R; Morris T
    J Nerv Ment Dis; 1996 Mar; 184(3):192-5. PubMed ID: 8600226
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluoxetine in the treatment of borderline and schizotypal personality disorders.
    Markovitz PJ; Calabrese JR; Schulz SC; Meltzer HY
    Am J Psychiatry; 1991 Aug; 148(8):1064-7. PubMed ID: 1853957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Self-mutilation from a forensic medicine viewpoint].
    Zinka B; Rauch E
    Hautarzt; 2007 Apr; 58(4):328-34. PubMed ID: 17048021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxcarbazepine for self-mutilating bulimic patients.
    Cordás TA; Tavares H; Calderoni DM; Stump GV; Ribeiro RB
    Int J Neuropsychopharmacol; 2006 Dec; 9(6):769-71. PubMed ID: 16893478
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic, developmental and personality correlates of self-mutilation in depressed patients.
    Joyce PR; McKenzie JM; Mulder RT; Luty SE; Sullivan PF; Miller AL; Kennedy MA
    Aust N Z J Psychiatry; 2006 Mar; 40(3):225-9. PubMed ID: 16476149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vomiting as a manifestation of borderline personality disorder in primary care.
    Johnson TM
    J Am Board Fam Pract; 1993; 6(4):385-94. PubMed ID: 8352042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder.
    Gardner DL; Cowdry RW
    Am J Psychiatry; 1986 Apr; 143(4):519-22. PubMed ID: 3513634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychological risk factors for dissociation and self-mutilation in female patients with borderline personality disorder.
    Zweig-Frank H; Paris J; Guzder J
    Can J Psychiatry; 1994 Jun; 39(5):259-64. PubMed ID: 8044740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venesection as a rare form of self-mutilation.
    Margo GM; Newman JS
    Am J Psychother; 1989 Jul; 43(3):427-32. PubMed ID: 2817153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Differential indications for psychotherapies in borderline personality disorder].
    Cailhol L; Bui E; Rouillon L; Bruno N; Lemoalle A; Faure K; Klein R; Lamy P; Guelfi JD; Schmitt L
    Encephale; 2011 May; 37 Suppl 1():S77-82. PubMed ID: 21600337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial.
    Bohus MJ; Landwehrmeyer GB; Stiglmayr CE; Limberger MF; Böhme R; Schmahl CG
    J Clin Psychiatry; 1999 Sep; 60(9):598-603. PubMed ID: 10520978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.